Search Results | Blood | American Society of Hematology

1-20 of 82

2 3 4 5

Sort by

Sort Order Select

Journal Articles

Real-World Validation of Molecular International Prognostic Scoring System (IPSS-M) for Myelodysplastic Syndromes

Blood (2022) 140 (Supplement 1): 1121–1124.

DOI: https://doi.org/10.1182/blood-2022-163634

Published: 2022

Journal Articles

Evaluation of Lenalidomide (LEN) Vs Placebo in Non-Transfusion Dependent Low Risk Del(5q) MDS Patients. Final Results of Sintra-REV Phase III International Multicenter Clinical Trial

Blood (2022) 140 (Supplement 1): 1109–1111.

DOI: https://doi.org/10.1182/blood-2022-168718

Published: 2022

Journal Articles

Treatment Patterns and Outcomes in Lower-Risk, Non-Del(5q) Myelodysplastic Syndromes: Findings from a Global Real-World Medical Record Review Study

Maria Diez-Campelo, Aylin Yucel, Ravi K. Goyal, Rohan C. Parikh, Elizabeth Esterberg, Maria Jimenez, Martina Sluga-O'Callaghan, Dimana Miteva, Hong Xiao, Ulrich Germing

Blood (2022) 140 (Supplement 1): 13308–13309.

DOI: https://doi.org/10.1182/blood-2022-156411

Published: 2022

Journal Articles

Long-Term Evolution of Somatic Mutations in Patients with Del(5q) MDS Early Treated with Lenalidomide in the Sintra-Rev Clinical Trial: Safe and Effecitive Approach?

Blood (2022) 140 (Supplement 1): 9740–9743.

DOI: https://doi.org/10.1182/blood-2022-168599

Published: 2022

Journal Articles

Bone Marrow Microenvironment Changes in Myelodysplastic Neoplasms and Its Relationship with Clonal Hematopoiesis and Disease Progression

Antonieta Molero Yordi, Soraya Peralta, Laura Gallur, Bárbara Tazón, Víctor Navarro Garcés, Silvia Saumell, Maria Julia Montoro, Olga Salamero, Ana Pérez González, Sara Garrido, Maria Sola, Tamara Jimenez, Félix López Cadenas, Teresa Ezponda, Ana Alfonso-Pierola, Lídia Altimiras, Maria Diez-Campelo, Felipe Prosper, David Valcárcel

Blood (2022) 140 (Supplement 1): 4024–4025.

DOI: https://doi.org/10.1182/blood-2022-163188

Published: 2022

Journal Articles

TP53 Allelic State in Myelodysplastic Syndromes with 5q Deletion

Maria Julia Montoro Gómez, Laura Palomo, Pablo Vidal, Francisco Fuster-Tormo, Esperanza Such, Margarita Ortega, Teresa González, Felix Lopez-Cadenas, Sara Garcia-Avila, Nieves Garcia-Gisbert, Elvira Mora Casterá, Eugenia Rivero, Francesc Bosch, Andrés Jerez, Maria Diez-Campelo, Francesc Solé, David Valcárcel

Blood (2022) 140 (Supplement 1): 6949–6951.

DOI: https://doi.org/10.1182/blood-2022-165257

Published: 2022

Journal Articles

Supervised Machine Learning Improves Risk Stratification in Newly Diagnosed Myelodysplastic Syndromes: An Analysis of the Spanish Group of Myelodysplastic Syndromes

Blood (2022) 140 (Supplement 1): 1132–1134.

DOI: https://doi.org/10.1182/blood-2022-159429

Published: 2022

Journal Articles

Multi-Modal Analysis and Federated Learning Approach for Classification and Personalized Prognostic Assessment in Myeloid Neoplasms

Blood (2022) 140 (Supplement 1): 9828–9830.

DOI: https://doi.org/10.1182/blood-2022-166802

Published: 2022

Journal Articles

ERCC6L2 in Early-Onset Adult Myelodysplastic Syndrome without Pre-Existing Disorder

Salvador Carrillo-Tornel, Tzu Hua Chen-Liang, Ana Yeguas Bermejo, Helena Pomares, Alessandro Liquori, Teresa González, Teresa Bernal del Castillo, Marta Santiago, Félix López Cadenas, Bernardo López Andrade, Raul Teruel Montoya, Esperanza Such, Francisca Maria Hernandez, Blanca Xicoy, Montserrat Arnan Sangerman, Francesc Solé, Jose Cervera, Maria Diez-Campelo, Andres Jerez

Blood (2022) 140 (Supplement 1): 4074–4075.

DOI: https://doi.org/10.1182/blood-2022-168759

Published: 2022

Journal Articles

Clinical Implications of p53 Dysfunction in Patients with Myelodysplastic Syndromes

Blood (2022) 140 (Supplement 1): 4001–4004.

DOI: https://doi.org/10.1182/blood-2022-166050

Published: 2022

Journal Articles

Characterization of Transcriptional Alterations Leading to Aberrant Myeloid Differentiation in Myelodysplastic Syndromes

Blood (2022) 140 (Supplement 1): 5852–5854.

DOI: https://doi.org/10.1182/blood-2022-166921

Published: 2022

Journal Articles

Synthetic Data Generation By Artificial Intelligence to Accelerate Translational Research and Precision Medicine in Hematological Malignancies

Blood (2022) 140 (Supplement 1): 9744–9746.

DOI: https://doi.org/10.1182/blood-2022-168646

Published: 2022

Journal Articles

Guiding the global evolution of cytogenetic testing for hematologic malignancies

Yassmine M. N. Akkari, Linda B. Baughn, Adrian M. Dubuc, Adam C. Smith, Mar Mallo, Paola Dal Cin, Maria Diez Campelo, Marta S. Gallego, Isabel Granada Font, Detlef T. Haase, Brigitte Schlegelberger, Irma Slavutsky, Cristina Mecucci, Ross L. Levine, Robert P. Hasserjian, Francesc Solé, Brynn Levy, Xinjie Xu

Blood (2022) 139 (15): 2273–2284.

DOI: https://doi.org/10.1182/blood.2021014309

Published: 2022

Journal Articles

Neutrophil and platelet increases with luspatercept in lower-risk MDS: secondary endpoints from the MEDALIST trial

Guillermo Garcia-Manero, Ghulam J. Mufti, Pierre Fenaux, Rena Buckstein, Valeria Santini, María Díez-Campelo, Carlo Finelli, Osman Ilhan, Mikkael A. Sekeres, Amer M. Zeidan, Rodrigo Ito, Jennie Zhang, Anita Rampersad, Daniel Sinsimer, Jay T. Backstrom, Uwe Platzbecker, Rami S. Komrokji

Blood (2022) 139 (4): 624–629.

DOI: https://doi.org/10.1182/blood.2021012589

Published: 2022

Journal Articles

Pevonedistat (PEV) + Azacitidine (AZA) Versus AZA Alone As First-Line Treatment for Patients with Higher-Risk Myelodysplastic Syndromes (MDS)/Chronic Myelomonocytic Leukemia (CMML) or Acute Myeloid Leukemia (AML) with 20-30% Marrow Blasts: The Randomized Phase 3 PANTHER Trial (NCT03268954)

Mikkael A. Sekeres, Larisa Girshova, Vadim A Doronin, Maria Diez-Campelo, David Valcarcel, Suman Kambhampati, Nora-Athina Viniou, Dariusz Woszczyk, Raquel De Paz Arias, Argiris Symeonidis, Achilles Anagnostopoulos, Eduardo Ciliao Munhoz, Uwe Platzbecker, Valeria Santini, Robert J. Fram, Ying Yuan, Douglas V. Faller, Lionel Ades

Blood (2021) 138 (Supplement 1): 242.

DOI: https://doi.org/10.1182/blood-2021-146154

Published: 2021

Journal Articles

Mutational Landscape of MDS Patients with HMA Failure Revealed By the Correlative Analysis from Inspire Trial

Koichi Takahashi, Anna Jonasova, Selina M. Luger, Aref Al-Kali, David Valcarcel, Erica D. Warlick, Maria Diez-Campelo, Michael K Keng, Feng Wang, Ken Furudate, Patrick S. Zbyszewski, Matthew Parris, Steven M. Fruchtman, Guillermo Garcia-Manero

Blood (2021) 138 (Supplement 1): 1517.

DOI: https://doi.org/10.1182/blood-2021-152048

Published: 2021

Journal Articles

On-Target Activity of Imetelstat Correlates with Clinical Benefits, Including Overall Survival (OS), in Heavily Transfused Non-Del(5q) Lower Risk MDS (LR-MDS) Relapsed/Refractory (R/R) to Erythropoiesis Stimulating Agents (ESAs)

Blood (2021) 138 (Supplement 1): 2598.

DOI: https://doi.org/10.1182/blood-2021-148876

Published: 2021

Journal Articles

Germline and Somatic Variants Co-Ocurrence Profile in Early Onset Adult Myelodysplastic Syndromes without a Preexisting Disorder

Blood (2021) 138 (Supplement 1): 2595.

DOI: https://doi.org/10.1182/blood-2021-152128

Published: 2021

Journal Articles

Clinical and Biological Characterization of Low Risk MDS Patients According to Ring Sideroblasts (RS). Comparison between the 3 Subgroups in WHO2017 Classification. Study from the Spanish MDS Registry

Blood (2021) 138 (Supplement 1): 2610.

DOI: https://doi.org/10.1182/blood-2021-152678

Published: 2021

Journal Articles

Deficiency of RPS14 Beyond the Haploinsufficient Loss in Del(5q)

Vera Adema, Sunisa Kongkiatkamon, Laura Palomo, Wencke Walter, Stephan Hutter, Thomas LaFramboise, Maria Diez-Campelo, Mar Mallo, Blanca Xicoy, Manja Meggendorfer, Hetty E. Carraway, Claudia Haferlach, Valeria Visconte, Francesc Sole, John Barnard, Torsten Haferlach, Jaroslaw P. Maciejewski

Blood (2021) 138 (Supplement 1): 2591.

DOI: https://doi.org/10.1182/blood-2021-151926

Published: 2021

2 3 4 5

NARROW

Real-World Validation of Molecular International Prognostic Scoring System (IPSS-M) for Myelodysplastic Syndromes

Evaluation of Lenalidomide (LEN) Vs Placebo in Non-Transfusion Dependent Low Risk Del(5q) MDS Patients. Final Results of Sintra-REV Phase III International Multicenter Clinical Trial

Treatment Patterns and Outcomes in Lower-Risk, Non-Del(5q) Myelodysplastic Syndromes: Findings from a Global Real-World Medical Record Review Study

Long-Term Evolution of Somatic Mutations in Patients with Del(5q) MDS Early Treated with Lenalidomide in the Sintra-Rev Clinical Trial: Safe and Effecitive Approach?

Bone Marrow Microenvironment Changes in Myelodysplastic Neoplasms and Its Relationship with Clonal Hematopoiesis and Disease Progression

TP53 Allelic State in Myelodysplastic Syndromes with 5q Deletion

Supervised Machine Learning Improves Risk Stratification in Newly Diagnosed Myelodysplastic Syndromes: An Analysis of the Spanish Group of Myelodysplastic Syndromes

Multi-Modal Analysis and Federated Learning Approach for Classification and Personalized Prognostic Assessment in Myeloid Neoplasms

ERCC6L2 in Early-Onset Adult Myelodysplastic Syndrome without Pre-Existing Disorder

Clinical Implications of p53 Dysfunction in Patients with Myelodysplastic Syndromes

Characterization of Transcriptional Alterations Leading to Aberrant Myeloid Differentiation in Myelodysplastic Syndromes

Synthetic Data Generation By Artificial Intelligence to Accelerate Translational Research and Precision Medicine in Hematological Malignancies

Guiding the global evolution of cytogenetic testing for hematologic malignancies

Neutrophil and platelet increases with luspatercept in lower-risk MDS: secondary endpoints from the MEDALIST trial

Pevonedistat (PEV) + Azacitidine (AZA) Versus AZA Alone As First-Line Treatment for Patients with Higher-Risk Myelodysplastic Syndromes (MDS)/Chronic Myelomonocytic Leukemia (CMML) or Acute Myeloid Leukemia (AML) with 20-30% Marrow Blasts: The Randomized Phase 3 PANTHER Trial (NCT03268954)

Mutational Landscape of MDS Patients with HMA Failure Revealed By the Correlative Analysis from Inspire Trial

On-Target Activity of Imetelstat Correlates with Clinical Benefits, Including Overall Survival (OS), in Heavily Transfused Non-Del(5q) Lower Risk MDS (LR-MDS) Relapsed/Refractory (R/R) to Erythropoiesis Stimulating Agents (ESAs)

Germline and Somatic Variants Co-Ocurrence Profile in Early Onset Adult Myelodysplastic Syndromes without a Preexisting Disorder

Clinical and Biological Characterization of Low Risk MDS Patients According to Ring Sideroblasts (RS). Comparison between the 3 Subgroups in WHO2017 Classification. Study from the Spanish MDS Registry

Deficiency of RPS14 Beyond the Haploinsufficient Loss in Del(5q)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only